DUBLIN, Dec. 17,
2024 /PRNewswire/ -- Theravance Biopharma,
Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH)
today announced that members of its management team will hold
investor meetings during the 43rd Annual J.P. Morgan Healthcare
Conference, January 13-16, 2025, in
San Francisco, CA.
To request a one-on-one meeting with the Theravance Biopharma
management team, please contact us at
investor.relations@theravance.com.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines
that Make a Difference® in people's lives. In
pursuit of its purpose, Theravance Biopharma leverages decades of
expertise, which has led to the development of FDA-approved
YUPELRI® (revefenacin) inhalation solution indicated for
the maintenance treatment of patients with chronic obstructive
pulmonary disease (COPD). Ampreloxetine, its late-stage
investigational once-daily norepinephrine reuptake inhibitor in
development for symptomatic neurogenic orthostatic hypotension
(nOH) in patients with Multiple System Atrophy (MSA), has the
potential to be a first in class therapy effective in treating a
constellation of cardinal symptoms in MSA patients. The Company is
committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the
Cross/Star logo are registered trademarks of the Theravance
Biopharma group of companies (in the U.S. and
certain other countries).
YUPELRI® is a registered trademark of Mylan
Specialty L.P., a Viatris company. Trademarks, trade names or
service marks of other companies appearing in this press release
are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download
multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-conduct-investor-meetings-during-the-jp-morgan-43rd-annual-healthcare-conference-302333431.html
SOURCE Theravance Biopharma, Inc.
